Temozolomide Teva
Authorised
This medicine is authorised for use in the European Union
temozolomide
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Temozolomide Teva is a medicine that contains the active substance temozolomide. It is available as capsules (5, 20, 100, 140, 180 and 250 mg).
Temozolomide Teva is a ‘generic medicine’. This means that Temozolomide Teva is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Temodal.
Temozolomide Teva is a cancer medicine. It is used to treat malignant glioma (brain tumours) in the following groups of patients:
- adults with newly diagnosed glioblastoma multiforme (an aggressive type of malignant glioma). Temozolomide Teva is used first with radiotherapy and then on its own;
- adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment. Temozolomide Teva is used on its own in these patients.
The medicine can only be obtained with a prescription.
Treatment with Temozolomide Teva should be prescribed by a doctor with experience in the treatment of brain tumours.
The dose of Temozolomide Teva depends on body surface area (calculated using the patient’s height and weight) and ranges from 75 to 200 mg per square metre, once a day. The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Teva is being used alone or with other treatments, and how the patient responds to treatment. Temozolomide Teva should be taken without food.
Patients may also need to take medicines to prevent vomiting before taking Temozolomide Teva. Temozolomide Teva should be used with caution in patients with severe liver problems or with kidney problems.
For full details, see the summary of product characteristics (also part of the EPAR).
The active substance in Temozolomide Teva, temozolomide, belongs to a group of cancer medicines called alkylating agents. In the body, temozolomide is converted to another compound called MTIC. MTIC binds to the DNA of cells while they are reproducing, which stops cell division. As a result, the cancer cells cannot divide, slowing down the growth of tumours.
Because Temozolomide Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
Because Temozolomide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
The CHMP concluded that, in accordance with EU requirements, Temozolomide Teva has been shown to have comparable quality and to be bioequivalent to Temodal. Therefore, the CHMP’s view was that, as for Temodal, the benefit outweighs the identified risk. The Committee recommended that Temozolomide Teva be given marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the EU for Temozolomide Teva on 28 January 2010.
For more information about treatment with Temozolomide Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Product information
Latest procedure affecting product information:
VR/0000170853
07/03/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Temozolomide Teva
- Active substance
- temozolomide
- International non-proprietary name (INN) or common name
- temozolomide
- Therapeutic area (MeSH)
- Glioma
- Anatomical therapeutic chemical (ATC) code
- L01AX03
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.
For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
This page was last updated on